Skip to main content

SciSparc Ltd.

corporate_fare Company Profile

SciSparc Ltd.

SPRC·NASDAQ·Life Sciences·CIK 0001611746

SciSparc Ltd. is a clinical-stage pharmaceutical company that develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110, which is being developed for the treatment of Tourette syndrome and Alzheimer's disease and agitation. Another program, SCI-210, targets autism spectrum disorder and status epilepticus. The company also develops CannAmide, an anti-inflammatory and chronic pain solution. In addition to its drug development, SciSparc Ltd. sells hemp seed oil-based products and other related items. The company has an agreement with Procaps for the development and commercial manufacturing of SCI-110, palmitoylethanolamide oral tablets, and CannAmide in softgel capsule form. SciSparc Ltd. also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial. This trial evaluates the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. Furthermore, the company has a collaboration with Clearmind Medicine Inc. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021.

SciSparc Ltd. (NASDAQ:SPRC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for SPRC at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • SciSparc Files $50M Universal Shelf Registration Amidst Nasdaq Compliance Concerns
  • SciSparc Subsidiary Granted US Patent for Cannabinoid-Enhanced Antimicrobial Technology
  • SciSparc Completes Endoscope IP Acquisition, Issues Highly Dilutive Warrants
  • SciSparc Announces Deeply Discounted $0.77M Offering Amid Nasdaq Delisting Threat
  • SciSparc Announces $766K Registered Direct Offering at Discounted Price

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$856K
Net Income
-$12.56M
Diluted EPS
$98.07
Op. Cash Flow
-$4.14M
Gross Profit
$631K
Operating Income
-$8.37M
Cash & Equivalents
$4.59M
Total Debt
$356K
Debt / Equity
0.07×
Net Margin
-14.68×
Shares Outstanding
365.44K sh
Source: 20-F · filed 2026-08-19 · accession 0001213900-26-091427

Insider Transactions

SPRC files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

$5.08
52-week range · as of 2026-08-19 $2.98 – $80.1
Market cap
$2.91M
Volume
11.6K (0.2× avg)
3-mo avg 64.2K
Live data · 2026-09-13 20:55 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed SPRC - Filings & News (Page 2)

SPRC
Feb 03, 2026, 4:36 PM EST
Filing Type: F-3
Importance Score:
9
SciSparc Files $50M Universal Shelf Registration Amidst Nasdaq Compliance Concerns
Price at Filing: $0.7545
Real-time Price: $5.08 info
Change: Reverse Stock Split info
Market Cap: $2.912M info
Sentiment: Negative
View Wiseek Article
SPRC
Feb 02, 2026, 4:01 PM EST
Filing Type: 6-K
Importance Score:
8
SciSparc Subsidiary Granted US Patent for Cannabinoid-Enhanced Antimicrobial Technology
Price at Filing: $0.753
Real-time Price: $5.08 info
Change: Reverse Stock Split info
Market Cap: $2.912M info
Sentiment: Positive
View Wiseek Article
SPRC
Jan 26, 2026, 4:01 PM EST
Filing Type: 6-K
Importance Score:
8
SciSparc Completes Endoscope IP Acquisition, Issues Highly Dilutive Warrants
Price at Filing: $0.930
Real-time Price: $5.08 info
Change: Reverse Stock Split info
Market Cap: $2.912M info
Sentiment: Neutral
View Wiseek Article
SPRC
Jan 14, 2026, 8:29 AM EST
Filing Type: 424B5
Importance Score:
9
SciSparc Announces Deeply Discounted $0.77M Offering Amid Nasdaq Delisting Threat
Price at Filing: $1.12
Real-time Price: $5.08 info
Change: Reverse Stock Split info
Market Cap: $2.912M info
Sentiment: Negative
View Wiseek Article
SPRC
Jan 13, 2026, 9:01 AM EST
Filing Type: 6-K
Importance Score:
8
SciSparc Announces $766K Registered Direct Offering at Discounted Price
Price at Filing: $1.20
Real-time Price: $5.08 info
Change: Reverse Stock Split info
Market Cap: $2.912M info
Sentiment: Negative
View Wiseek Article
SPRC
Jan 13, 2026, 7:10 AM EST
Filing Type: 6-K
Importance Score:
9
SciSparc to Acquire Endoscope Patent Portfolio, Issuing 19.99% Equity for Entry into Multi-Billion Dollar Market
Price at Filing: $1.20
Real-time Price: $5.08 info
Change: Reverse Stock Split info
Market Cap: $2.912M info
Sentiment: Neutral
View Wiseek Article
SPRC
Jan 12, 2026, 4:09 PM EST
Filing Type: 6-K
Importance Score:
8
SciSparc Receives Nasdaq Non-Compliance Notice for Minimum Stockholders' Equity
Price at Filing: $1.45
Real-time Price: $5.08 info
Change: Reverse Stock Split info
Market Cap: $2.912M info
Sentiment: Negative
View Wiseek Article
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets